BI-MODAL HYALURONATE
First Claim
Patent Images
1. A formulation comprising a first fraction of a first ophthalmically acceptable compound and a second fraction of a second ophthalmically acceptable compound, wherein the first and second fractions are present in a total concentration of at least 10 mg/ml, and the first and second fractions have average molecular mass that differ by at least 4 million.
5 Assignments
0 Petitions
Accused Products
Abstract
Formulations and methods for protecting cell layers and tissues exposed to trauma are disclosed. Different molecular mass fractions of the same polymer can be used to better control the physical and chemical properties of the formulation. In this manner the benefits of both fractions, and not just the benefits of the average of the fractions, can be seen in the formulation.
-
Citations
28 Claims
- 1. A formulation comprising a first fraction of a first ophthalmically acceptable compound and a second fraction of a second ophthalmically acceptable compound, wherein the first and second fractions are present in a total concentration of at least 10 mg/ml, and the first and second fractions have average molecular mass that differ by at least 4 million.
- 11. A formulation comprising at least 5 mg/ml each of first and second ophthalmically acceptable, viscoelastic compounds, the first compound having an average molecular mass of less than 150,000, and the second compound having an average molecular mass of at least 2 million.
- 13. A formulation comprising at least 5 mg/ml each of first and second ophthalmically acceptable, viscoelastic compounds, the first compound having an average molecular mass of less than 2 million, and the second compound having an average molecular mass of at least 5 million.
- 16. A formulation comprising at least 5 mg/ml each of first and second ophthalmically acceptable, viscoelastic compounds, the concentrations and average molecular mass of the compounds selected such that at a shear rate of 1, the viscosity of the formulation is between 0, 1 and 10 Pas, and at zero shear, the viscosity of the formulation is between 50 and 100,000 Pas.
- 23. A formulation comprising a first fraction of a first ophthalmically acceptable compound and a second fraction of a second ophthalmically acceptable compound, wherein the first and second fractions have average molecular masses that differ by at least 4 million, and wherein the difference in average molecular mass accentuates the desirable characteristics of the OVD.
- 26. A formulation comprising a first fraction of a first ophthalmically acceptable compound and a second fraction of a second ophthalmically acceptable compound, wherein the first and second fractions have average molecular masses that differ by at least 4 million, and wherein the difference in average molecular mass accentuates characteristics of one of the fractions.
Specification